Riskpilot← Back to searchSign inGet full accessCAND PHARM C. CRISTOFFERSEN AS
ASActiveOrg 989174401Rødmyrsvingen 53, 3735 SkienWholesale of wood, construction materials and sanitary equipment · NACE 4683Est. 20060 employees
Revenue 2024
NOK 0
EBITDA margin
—
+2% vs 2023
Equity ratio
80.6%
Financial strength
Net profit 2024
NOK 9,6M
+15% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -40K | +2% |
| Net profit | NOK 9,6M | +15% |
| Total assets | NOK 36,8M | +11% |
| Equity | NOK 29,7M | +10% |
| Employees | 0 | — |
Legal name
CAND PHARM C. CRISTOFFERSEN AS
Org number
989174401
Legal form
Aksjeselskap
NACE code
4683 · Wholesale of wood, construction materials and sanitary equipment
Founded
13. januar 2006
Share capital
NOK 2 500 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Morten christian christoffersen
Company purpose
Kjøp og salg av aksjer og andeler, herunder eie og forvalte eiendommer samt annet som naturlig hører til.
Address
Rødmyrsvingen 53, 3735 Skien
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −28 | −30 | −37 | −41 | −40 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −28 | −30 | −37 | −41 | −40 |
| Net financials | 11 271 | 23 461 | 8 702 | 8 469 | 9 813 |
| Profit before tax | 11 244 | 23 431 | 8 665 | 8 427 | 9 773 |
| Tax | 45 | 3 | 27 | 94 | 159 |
| Net profit | 11 199 | 23 427 | 8 637 | 8 333 | 9 613 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 17 712 | 26 098 | 30 759 | 33 159 | 36 838 |
| Equity | 13 667 | 22 094 | 24 732 | 27 065 | 29 679 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 045 | 4 003 | 6 027 | 6 094 | 7 159 |
| Total debt | 4 045 | 4 003 | 6 027 | 6 094 | 7 159 |
EBITDA margin
-4023500.0%
This company
15.8%
Market median
-25465290% vs market
20202024
Equity ratio
80.6%
This company
38.2%
Market median
+111% vs market
20202024
Return on equity
32.4%
This company
18.4%
Market median
+76% vs market
20202024
Net profit margin
961345200.0%
This company
8.1%
Market median
+11868459159% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.24×
This company
0.62×
Market median
+61% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GH Deputy Member | Deputy Member | 2006 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 99.98% | 99.98% | 2022 | |
| Individual | 0.02% | 0.02% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CAND PHARM C. CRISTOFFERSEN AS 
C. Christoffersen AsBoard members of CAND PHARM C. CRISTOFFERSEN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gro Heike Hauff Christoffersen | Deputy Member | 0 companies |
| Morten Christian Christoffersen | Chairman | 0 companies |